As previous studies in cancer have shown that the order of administration of SMAC mimetics and MG1 may affect the cell viability outcomes (4, 5), we evaluated whether pretreatment (rather than concurrent treatment) with SMAC mimetics would increase MG1-mediated cell death. The gene discussed is MUC5B; the disease is cancer.